182 related articles for article (PubMed ID: 24553243)
21. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A
Cancer Immunol Immunother; 2017 Mar; 66(3):367-378. PubMed ID: 27933426
[TBL] [Abstract][Full Text] [Related]
22. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
Smith-Jones PM; Pandit-Taskar N; Cao W; O'Donoghue J; Philips MD; Carrasquillo J; Konner JA; Old LJ; Larson SM
Nucl Med Biol; 2008 Apr; 35(3):343-51. PubMed ID: 18355690
[TBL] [Abstract][Full Text] [Related]
23. Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.
Lange SE; Zheleznyak A; Studer M; O'Shannessy DJ; Lapi SE; Van Tine BA
Oncotarget; 2016 Mar; 7(11):13082-92. PubMed ID: 26909615
[TBL] [Abstract][Full Text] [Related]
24. Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle JK; Brioschi M; de Tiani M; Wetterwald L; Atsaves V; Abram-Saliba J; Petrova TV; Coukos G; Dunn SM
Cell Rep Med; 2021 Aug; 2(8):100362. PubMed ID: 34467246
[TBL] [Abstract][Full Text] [Related]
25. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W
Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138
[TBL] [Abstract][Full Text] [Related]
26. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells.
Christian S; Winkler R; Helfrich I; Boos AM; Besemfelder E; Schadendorf D; Augustin HG
Am J Pathol; 2008 Feb; 172(2):486-94. PubMed ID: 18187565
[TBL] [Abstract][Full Text] [Related]
27. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
28. TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
Matthaiou EI; Guo Y; Barar J; Sandaltzopoulos R; Kandalaft LE; Li C; Coukos G; Omidi Y
Bioimpacts; 2022; 12(1):65-86. PubMed ID: 35087718
[No Abstract] [Full Text] [Related]
29. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin.
Rossin R; Berndorff D; Friebe M; Dinkelborg LM; Welch MJ
J Nucl Med; 2007 Jul; 48(7):1172-9. PubMed ID: 17574989
[TBL] [Abstract][Full Text] [Related]
30. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors.
Nanda A; Karim B; Peng Z; Liu G; Qiu W; Gan C; Vogelstein B; St Croix B; Kinzler KW; Huso DL
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3351-6. PubMed ID: 16492758
[TBL] [Abstract][Full Text] [Related]
31. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
32. TEM1 up-regulates MMP-2 and promotes ECM remodeling for facilitating invasion and migration of uterine sarcoma.
Wu C; Sun W; Shen D; Li H; Tong X; Guo Y
Discov Oncol; 2023 Jan; 14(1):5. PubMed ID: 36639546
[TBL] [Abstract][Full Text] [Related]
33. Role of tumor endothelial marker 1 (Endosialin/CD248) lectin-like domain in lipopolysaccharide-induced macrophage activation and sepsis in mice.
Cheng TL; Lin YS; Hong YK; Ma CY; Tsai HW; Shi GY; Wu HL; Lai CH
Transl Res; 2021 Jun; 232():150-162. PubMed ID: 33737161
[TBL] [Abstract][Full Text] [Related]
34. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
35. Tumor Endothelial Marker 1 (TEM1/Endosialin/CD248) Enhances Wound Healing by Interacting with Platelet-Derived Growth Factor Receptors.
Hong YK; Lee YC; Cheng TL; Lai CH; Hsu CK; Kuo CH; Hsu YY; Li JT; Chang BI; Ma CY; Lin SW; Wang KC; Shi GY; Wu HL
J Invest Dermatol; 2019 Oct; 139(10):2204-2214.e7. PubMed ID: 30986375
[TBL] [Abstract][Full Text] [Related]
36. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.
Ugel S; Facciponte JG; De Sanctis F; Facciabene A
Cancer Immunol Immunother; 2015 Oct; 64(10):1339-48. PubMed ID: 26267042
[TBL] [Abstract][Full Text] [Related]
37. Gene targeting and expression analysis of mouse Tem1/endosialin using a lacZ reporter.
Huang HP; Hong CL; Kao CY; Lin SW; Lin SR; Wu HL; Shi GY; You LR; Wu CL; Yu IS
Gene Expr Patterns; 2011; 11(5-6):316-26. PubMed ID: 21402174
[TBL] [Abstract][Full Text] [Related]
38. ImmunoPET of Malignant and Normal B Cells with
Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
[No Abstract] [Full Text] [Related]
39. ImmunoPET, [
Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK
Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348
[TBL] [Abstract][Full Text] [Related]
40. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
